AUDITOR – Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant Study
Principal contacts
Eric de Groot - Imagelabonline & Cardiovascular, Eindhoven and Lunteren, the Netherlands
John J. P. Kastelein - University of Amsterdam, Amsterdam, the Netherlands
Study design
The Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant Study (AUDITOR) is a two-arm clinical trial based at 64 centres in North America (USA, Canada) and Europe (France, the Netherlands, Spain, UK). The principal aim of the trial was to investigate the effect of Rimonabant (20mg/day) versus placebo on carotid intima-media thickness progression in patients with abdominal obesity and metabolic syndrome. Individuals were eligible for inclusion if they were older or equal to 55 years, had abdominal obesity, and met additional criteria for the Metabolic Syndrome. The institutional review boards of all participating centres approved the protocol. Written informed consent was obtained from all patients.
Link to study webpage – https://clinicaltrials.gov/ct2/show/NCT00228176
Key publications
Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial. Heart. 2011 Jul;97(14):1143-50